Chris O'Brien Lifehouse

Unspecified (Unknown)

Start Date End Date Funded Value

Relevance

CSV

25 50 100

£2,582,844

Mar 24 - Mar 27

Targeting Inhibitory kappa B kinase alpha (IKKalpha): a new treatment paradigm for inflammatory-driven cancers

MRC award to University of Strathclyde and Simon Mackay

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}